Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

178 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Volanesorsen to Prevent Acute Pancreatitis in Hypertriglyceridemia.
Alexander VJ, Karwatowska-Prokopczuk E, Prohaska TA, Li L, Geary RS, Gouni-Berthold I, Oral EA, Hegele RA, Stroes ESG, Witztum JL, Tsimikas S. Alexander VJ, et al. Among authors: gouni berthold i. N Engl J Med. 2024 Feb 1;390(5):476-477. doi: 10.1056/NEJMc2306575. N Engl J Med. 2024. PMID: 38294982 No abstract available.
Corrigendum to "Volanesorsen and triglyceride levels in familial chylomicronemia syndrome: Long-term efficacy and safety data from patients in an open-label extension trial" [Journal of Clinical Lipidology, Volume 17, Issue 3, May-June 2023, Pages 342-355].
Witztum JL, Gaudet D, Arca M, Jones A, Soran H, Gouni-Berthold I, Stroes ESG, Alexander VJ, Jones R, Watts L, Xia S, Tsimikas S. Witztum JL, et al. Among authors: gouni berthold i. J Clin Lipidol. 2024 May-Jun;18(3):e482-e483. doi: 10.1016/j.jacl.2023.09.010. Epub 2023 Oct 13. J Clin Lipidol. 2024. PMID: 38565460 No abstract available.
PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial.
Raal FJ, Stein EA, Dufour R, Turner T, Civeira F, Burgess L, Langslet G, Scott R, Olsson AG, Sullivan D, Hovingh GK, Cariou B, Gouni-Berthold I, Somaratne R, Bridges I, Scott R, Wasserman SM, Gaudet D; RUTHERFORD-2 Investigators. Raal FJ, et al. Lancet. 2015 Jan 24;385(9965):331-40. doi: 10.1016/S0140-6736(14)61399-4. Epub 2014 Oct 1. Lancet. 2015. PMID: 25282519 Clinical Trial.
Association of BMI, lipid-lowering medication, and age with prevalence of type 2 diabetes in adults with heterozygous familial hypercholesterolaemia: a worldwide cross-sectional study.
European Atherosclerosis Society Familial Hypercholesterolaemia Studies Collaboration (EAS FHSC). European Atherosclerosis Society Familial Hypercholesterolaemia Studies Collaboration (EAS FHSC). Lancet Diabetes Endocrinol. 2024 Nov;12(11):811-823. doi: 10.1016/S2213-8587(24)00221-3. Epub 2024 Oct 4. Lancet Diabetes Endocrinol. 2024. PMID: 39374602 Free article.
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.
Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR; FOURIER Steering Committee and Investigators. Sabatine MS, et al. N Engl J Med. 2017 May 4;376(18):1713-1722. doi: 10.1056/NEJMoa1615664. Epub 2017 Mar 17. N Engl J Med. 2017. PMID: 28304224 Free article. Clinical Trial.
2024 Recommendations on the Optimal Use of Lipid-Lowering Therapy in Established Atherosclerotic Cardiovascular Disease and Following Acute Coronary Syndromes: A Position Paper of the International Lipid Expert Panel (ILEP).
Banach M, Reiner Ž, Surma S, Bajraktari G, Bielecka-Dabrowa A, Bunc M, Bytyçi I, Ceska R, Cicero AFG, Dudek D, Dyrbuś K, Fedacko J, Fras Z, Gaita D, Gavish D, Gierlotka M, Gil R, Gouni-Berthold I, Jankowski P, Járai Z, Jóźwiak J, Katsiki N, Latkovskis G, Magda SL, Margetic E, Margoczy R, Mitchenko O, Durak-Nalbantic A, Ostadal P, Paragh G, Petrulioniene Z, Paneni F, Pećin I, Pella D, Postadzhiyan A, Stoian AP, Trbusic M, Udroiu CA, Viigimaa M, Vinereanu D, Vlachopoulos C, Vrablik M, Vulic D, Penson PE; International Lipid Expert Panel (ILEP). Banach M, et al. Among authors: gouni berthold i. Drugs. 2024 Dec;84(12):1541-1577. doi: 10.1007/s40265-024-02105-5. Epub 2024 Nov 4. Drugs. 2024. PMID: 39497020 Free PMC article.
Beyond LDL-C: unravelling the residual atherosclerotic cardiovascular disease risk landscape-focus on hypertriglyceridaemia.
Bashir B, Schofield J, Downie P, France M, Ashcroft DM, Wright AK, Romeo S, Gouni-Berthold I, Maan A, Durrington PN, Soran H. Bashir B, et al. Among authors: gouni berthold i. Front Cardiovasc Med. 2024 Aug 7;11:1389106. doi: 10.3389/fcvm.2024.1389106. eCollection 2024. Front Cardiovasc Med. 2024. PMID: 39171323 Free PMC article. Review.
Quality of life in patients with statin intolerance: a multicentre prospective registry study.
Stürzebecher PE, Gouni-Berthold I, Mateev C, Frenzel O, Erbe S, Boeckel JN, Scholz M, Schatz U, Weingärtner O, Kassner U, Laufs U; Statin Intolerance Registry investigators. Stürzebecher PE, et al. Among authors: gouni berthold i. Lancet Reg Health Eur. 2024 Jul 1;43:100981. doi: 10.1016/j.lanepe.2024.100981. eCollection 2024 Aug. Lancet Reg Health Eur. 2024. PMID: 39045127 Free PMC article.
178 results